



Corres. and Mail

BOX AF

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

OCT 17 2001

45D-1750 (81841.0041)

AF/1645

In re application of:

R. J. Obremski, et al.

Serial No: 09/063,978

Filed: April 21, 1998

For: DETECTION OF VERY LOW QUANTITIES OF  
ANALYTE BOUND TO A SOLID PHASE

Art Unit: 1645

Examiner: J. Hines

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: BOX AF, Commissioner for Patents Washington D.C. 20231, on October 12, 2001

Date of Deposit

Wei-Ning Yang, Reg. No. 38,690

Name

10/12/01

Signature

Date

BOX AF  
Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Transmitted herewith is an amendment in the above-identified application.

- Change of Correspondence Address is enclosed.  
 No additional fee is required.

The fee has been calculated as shown below:

	(Col. 1) CLAIMS REMAINING AFTER AMENDMENT		(Col. 2) HIGHEST NUMBER PREVIOUSLY PAID FOR		(Col. 3) PRESENT EXTRA*	LG/SM \$ ENTITY FEE		ADD'L FEE DUE
TOTAL CLAIMS FEE	28	-	28	**	0	LG=\$18 SM=\$9	\$	\$
INDEPENDENT CLAIMS FEE	3	-	3	***	0	LG=\$80 SM=\$40	\$	\$ 0
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIMS							LARGE ENTITY FEE = \$270 SMALL ENTITY FEE = \$135	\$
							TOTAL	\$

- \* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
- \*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.
- \*\*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space. The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box on Col. 1 of a prior amendment or the number of claims originally filed.

- A check in the amount of \$\_\_\_\_ to cover the additional claims fee is enclosed. **A copy of this sheet is enclosed.**
- A check in the amount of \$\_\_\_\_ to cover the extension fee is enclosed. **A copy of this sheet is enclosed.**
- The Commissioner is hereby authorized to charge any deficiencies of fees associated with this communication or credit any overpayment to Deposit Account No. 50-1314. **A copy of this sheet is enclosed.**
- Any filing fees under 37 C.F.R. § 1.16 for the presentation of extra claims
- Any patent application processing fees under 37 C.F.R. § 1.17

Respectfully submitted,  
HOGAN & HARTSON L.L.P.

By:

Wei-Ning Yang  
Registration No. 38,690  
Attorney for Applicant(s)

Date: October 12, 2001

Biltmore Tower  
500 South Grand Avenue, Suite 1900  
Telephone: 213 337-6700  
Facsimile: 213 337-6701

RECEIVED

OCT 17 2001

TECH CENTER 1600/2900

PATENT  
45D-1750  
(81841.0041)

AFTER FINAL RESPONSE UNDER 37 C.F.R. §1.116  
EXPEDITED PROCEDURE



H(NE)  
JL  
Linda  
10/23/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

R. J. Obremski, *et al.*

Serial No: 09/063,978

Filed: April 21, 1998

For: DETECTION OF VERY LOW  
QUANTITIES OF ANALYTE  
BOUND TO A SOLID PHASE

Art Unit: 1645

Examiner: J. Hines

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:  
Commissioner for Patents,  
Washington D.C. 20231, on  
October 12, 2001  
Date of Deposit  
Wei-Ning Yang, Reg. No. 38,690  
Name \_\_\_\_\_  
Signature \_\_\_\_\_ Date 10/12/01

**RESPONSE UNDER**  
**37 C.F.R. § 1.116**

BOX AF  
Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In response to the final Office Action dated August 14, 2001, favorable reconsideration is requested in view of the following remarks.

**REMARKS:**

Claims 1-28 are pending in the application and have been rejected. Claims 1-28 are presented for further prosecution. Favorable reconsideration of the application is requested in light of the remarks that follow.

The rejection of claims 1-4, 13-19, 21, and 23-26 under 35 U.S.C. § 103(a) as being unpatentable over Ekins *et al.*, EP 304,202 (the '202 patent), in view of Ekins *et al.*, J. of Clinical Immunoassay (Immunoassay reference), is maintained. Claims 27 and 28 are also rejected under 35 U.S.C. § 103(a) as being unpatentable over the same references. These rejections are respectfully traversed.